M
Mariell Jessup
Researcher at American Heart Association
Publications - 269
Citations - 80056
Mariell Jessup is an academic researcher from American Heart Association. The author has contributed to research in topics: Heart failure & Transplantation. The author has an hindex of 69, co-authored 261 publications receiving 72097 citations. Previous affiliations of Mariell Jessup include Temple University & University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
Stuart D. Katz,Spencer H. Kubo,Mariell Jessup,Suzanne Brozena,Janice M. Troha,Janice Wahl,Jay N. Cohn,Edmund H. Sonnenblick,Thierry H. LeJemtel +8 more
TL;DR: Pimobendan acutely improves resting left ventricular performance and chronically increases exercise duration and peak oxygen uptake in patients with severe congestive heart failure concomitantly treated with digoxin, diuretics, and angiotensin-converting enzyme inhibitors.
Journal ArticleDOI
Diagnosis and Management of Iron-induced Heart Disease in Cooley's Anemia
TL;DR: Based on successful prevention of heart failure with ACE inhibitors in other forms of cardiomyopathy, multicenter trials are suggested to explore methods to stabilize cardiac function in patients at risk for iron‐induced heart disease.
Journal ArticleDOI
A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home
Susan C. Brozena,Carol Twomey,Lee R. Goldberg,Shashank Desai,Brian M. Drachman,Andrew Kao,Eric Popjes,Ross Zimmer,Mariell Jessup +8 more
TL;DR: Continuous intravenous milrinone therapy can be safely administered at home in selected patients with advanced heart failure who are listed for transplant and this strategy may be an acceptable alternative to prolonged hospitalization for patients dependent on continuous inotropic support.
Journal ArticleDOI
Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure
Douglas L. Mann,Michael A. Acker,Mariell Jessup,Hani N. Sabbah,Randall C. Starling,Spencer H. Kubo +5 more
TL;DR: The Acorn Pivotal Trial will formally test the hypothesis that preventing LV remodeling using a passive cardiac support device will favorably impact the untoward natural history of heart failure and thus represents an important departure from all previous medical and device studies that have been reported to date.
Journal ArticleDOI
Ventricular Assist Device Implant in the Elderly Is Associated With Increased, but Respectable Risk: A Multi-Institutional Study
Pavan Atluri,Andrew B. Goldstone,Dale Kobrin,Jeffrey E. Cohen,John W. MacArthur,Jessica L. Howard,Mariell Jessup,J. Eduardo Rame,Michael A. Acker,Y. Joseph Woo +9 more
TL;DR: Patients age 70 and older were more hemodynamically stable pre-VAD implant as evidenced by INTERMACS profile and inotrope dependence, and advanced age was revealed as a predictor of increased mortality after CF LVAD implantation.